Skip to main content

Peer Review reports

From: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Original Submission
24 Jun 2023 Submitted Original manuscript
4 Aug 2023 Reviewed Reviewer Report
8 Sep 2023 Reviewed Reviewer Report
7 Nov 2023 Author responded Author comments - Daniele Marinelli
Resubmission - Version 2
7 Nov 2023 Submitted Manuscript version 2
14 Dec 2023 Reviewed Reviewer Report
20 Mar 2024 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
20 Mar 2024 Editorially accepted
8 Apr 2024 Article published 10.1186/s12885-024-12155-3

You can find further information about peer review here.

Back to article page